 |
Australia's CSL ($CSL) has several promising recombinant factor hemophilia treatments in its pipeline and now it has a $250 million plant ready to produce them. The company this week opened the new plant in Melbourne, which sits next to a CSL facility that makes blood plasma products. The expansion, which added 240 jobs, got financial support from both the federal and Victorian state governments, according to The Australian. It is expected to quadruple the plant's manufacturing capacity by 2018. The company said it will initially produce its longer acting blood factor (rVIIa-FP), which is in clinical trials, and if approved, for commercial distribution. The plant will also be used to provide additional production for its Privigen immunoglobulin product, the newspaper said. Release | Story